Effects of symbiotic and vitamin E supplementation on blood pressure, nitric oxide and inflammatory factors in non-alcoholic fatty liver disease.
Effects of symbiotic and vitamin E supplementation on blood pressure, nitric oxide and inflammatory factors in non-alcoholic fatty liver disease.
复制标题
DOI：
10.17179/excli2016-846
复制
发表时间：
2017
期刊：
影响因子：
4.6
通讯作者：
Shidfar F
中科院分区：
文献类型：
--
作者：
Ekhlasi G;Zarrati M;Agah S;Hosseini AF;Hosseini S;Shidfar S;Soltani Aarbshahi SS;Razmpoosh E;Shidfar F
非酒精性脂肪性肝病（NAFLD）已被认为与血压改变密切相关。本研究旨在确定补充共生菌和维生素E对NAFLD患者血压和炎症指标的影响。这项随机、双盲、安慰剂对照试验在60名年龄在25至64岁的NAFLD患者中进行。参与者被随机分为四组，接受400 IU α -生育酚和2 × 108 CFU/g的共生补充剂，持续8周。在基线和干预8周后评估人体测量参数、收缩压（SBP）和舒张压（DBP）、血清丙二醛（MDA）、一氧化氮（NO）和肿瘤坏死因子α (TNFα)。干预8周后，与安慰剂相比，共生与α -生育酚联合用药、共生与α -生育酚单独用药显著降低收缩压（-17.07±2.1、-16.07±3.56、-1.73±2.25和-1.55±3.01 mmHg， P=0.01）、血清MDA（-1.19±0.5、-0.12±0.65、0.14±0.64和0.16±0.34 nmol/mL， P<0.001）、血清tnf - α（-15.62±13.93、-9.24±7.12、-11.44±15.47和3.01±1.71 pg/ mL， P<0.001）浓度。血清AST（-11.36±4.52,-7.43±8.58,-5.93±6.61和- 2.5±5.75 μmol/L, P <0.001）、ALT（-12.79±3.65,-3.66±6.81,-6.54±7.66和4.16±3.43 μmol/L, P <0.001）和ALP（-26.8±11.1,-4.56±9.22,-14.48±12.22和5.19±2.64 μmol/L, P <0.001）显著降低。DBP和血清NO浓度变化不显著。NAFLD患者补充α -生育酚和共生菌可降低收缩压、血清MDA、TNFα水平和肝酶水平；但不影响舒张压和血清NO浓度。
Non-alcoholic fatty liver disease (NAFLD) has been suggested to be well correlated with altered blood pressure. This study was conducted to determine the effects of symbiotic and vitamin E supplementation on blood pressure and inflammatory indices of patients with NAFLD. This randomized, double-blind, placebo-controlled trial was performed among 60 NAFLD patients aged 25 to 64 years old. Participants were randomly divided into four groups to receive a 400 IU alpha-tocopherol and 2 × 108 CFU/g symbiotic supplement for 8 weeks. The anthropometric parameters, systolic blood pressure (SBP) and diastolic blood pressure (DBP), serum malondialdehyde (MDA), nitric oxide (NO) and tumor necrosis factor α (TNFα) were assessed at baseline and after 8 weeks of intervention. After 8 weeks of intervention, combined symbiotic and alpha-tocopherol, symbiotic and alpha-tocopherol alone administration, compared with the placebo, resulted in significant decreases in SBP (-17.07±2.1, -16.07±3.56, -1.73±2.25 and -1.55±3.01 mmHg, P=0.01), serum MDA (-1.19±0.5, -0.12±0.65, 0.14 ± 0.64 and 0.16±0.34 nmol/mL, P<0.001), serum TNFα (-15.62±13.93, -9.24±7.12, -11.44 ± 15.47 and 3.01±1.71 pg/ml, P<0.001) concentrations. A significant decrease in serum AST (-11.36±4.52, -7.43±8.58, -5.93±6.61 and 2.5±5.75 μmol/L, P <0.001), ALT (-12.79±3.65, -3.66±6.81, -6.54±7.66 and 4.16±3.43 μmol/L, P <0.001) and ALP (-26.8±11.1, -4.56±9.22, -14.48±12.22 and 5.19±2.64 μmol/L, P <0.001) was seen. Variations in DBP and serum NO concentration were not significant. Alpha-tocopherol and symbiotic supplementation among patients with NAFLD resulted in decreased SBP, serum MDA, TNFα levels and enzymes liver; however, they did not affect DBP and serum NO concentration.